Previous close | 255.28 |
Open | 257.21 |
Bid | 259.93 x 100 |
Ask | 263.91 x 100 |
Day's range | 251.43 - 265.94 |
52-week range | 127.29 - 265.94 |
Volume | |
Avg. volume | 67,251 |
Market cap | 2.011B |
Beta (5Y monthly) | 0.84 |
PE ratio (TTM) | 42.21 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NEWBURYPORT, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a designer and custom manufacturer of comprehensive solutions primarily for the medical market, today reported net income of $12.7 million or $1.64 per diluted common share outstanding for its first quarter ended March 31, 2024, compared to net income of $9.7 million or $1.27 per diluted common share outstanding for the first quarter of 2023. Net Sales for the first quarter were $105.0 million compared to
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company’s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effe
NEWBURYPORT, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT) an Innovative designer and custom manufacturer of components, subassemblies, products, and packaging primarily for the medical market today announced that Chairman and Chief Executive Officer R. Jeffrey Bailly and Chief Financial Officer Ron Lataille will participate in the upcoming KeyBanc Capital Markets 4th Annual Life Sciences and MedTech Investor Forum to be held virtually on March 19 and 20, 2024.